ALDX

Aldeyra is a clinical-stage biotech with zero product revenue across five straight years of losses (-$33.8M in FY2025) and an accumulated deficit of -$484M. The entire equity thesis rests on a single asset, reproxalap, which the filing concedes has already drawn multiple FDA Complete Response Letters: 'Our success... depends on whether we successfully address the issues raised by the FDA in the reproxalap Complete Response Letters.' That is a textbook binary regulatory event, not a fundamentals story. With no revenue line to model, traditional valuation (P/E, P/S, ROE of -76.5%) is meaningless — you are buying a lottery ticket on an FDA decision and on whether AbbVie exercises its option.

The balance sheet is the more urgent problem. Cash is $70.0M, but operating cash burn was -$33.3M last year, leaving roughly two years of runway — and that ignores the funding cliff in the filing: the Hercules Credit Facility had $15.0M outstanding with a Maturity Date of April 1, 2026, which is why current debt exploded +48,509% to $15.2M. As of today (June 2026) that note has come due, consuming a chunk of the cash position. Management is explicit it 'will need to raise additional capital in the form of debt or equity,' and it already has a $75M Jefferies ATM armed and ready — meaning near-certain dilution against a 60.2M share base at a $2.05 stock. R&D spend was cut -46.8%, which preserves cash but also signals a company throttling its pipeline to survive rather than investing to win.